Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock
https://www.sec.gov/Archives/edgar/data/1339005/000114036126035625/ny20081537x1_s3.htm
Stocks · News reference
Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 66.25 percent increase over losses of $(3.20) per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations
-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.
Femasys shares are trading higher after the company announced that the U.S. Food and Drug Administration has approved the company’s modular premarket approval application pathway for FemBloc.